SOC, I was trying to suggest that that kind of thing is unlikely, in my view anyway, to be the reason why some people respond to Ritux and some don't - i.e. it's probably not going to be explained by one group having one infection and the other group another infection. What I think we will see instead is that the responders are all at a similar stage of the illness, even if they got there by different routes. Since both EBV and Lyme can persist in B cells, it seems quite likely that both can cause B cell dysfunction that is responsive to Rituximab treatment. I think the amount of time someone has been ill, and how severe their illness is, will determine how much B cell dysfunction they have, and thus how they respond to Rituximab treatment.
On that note, is it just me seeing what I expect to see, or were the major responders in this study ill for longer, on average, than the non- and minor responders?
On that note, is it just me seeing what I expect to see, or were the major responders in this study ill for longer, on average, than the non- and minor responders?